The Claim
Petrelintide has a terminal half-life of approximately 10 days following subcutaneous administration, achieves steady-state pharmacokinetics after five doses, and exhibits dose-proportional exposure across the 0.6–9.0 mg range.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When injected under the skin, petrelintide remains active in the body for about 10 days, reaches stable blood levels after five doses, and the amount in the blood increases proportionally with the dose between 0.6 and 9.0 milligrams.
See the scientific wording
Petrelintide has a terminal half-life of approximately 10 days following subcutaneous administration, enabling once-weekly dosing with steady-state pharmacokinetics achieved after five doses and dose-proportional exposure across the 0.6–9.0 mg range.
Petrelintide is a modified peptide with a fatty acid chain attached that sticks tightly to a protein in the blood called albumin. This binding slows down how fast the body removes petrelintide, so it stays in the bloodstream for about 10 days. Because the amount of petrelintide in the blood increases evenly as the dose goes up, and it takes five weekly doses to reach a stable level, the body processes it in a predictable, linear way.
What the research says
1 studyThe study found that petrelintide stays in the body for about 10 days after injection, so you only need to take it once a week, and the amount in your blood goes up evenly as you take more of the drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.